The stock hit $23.26 in late trading, cooling from a $28.53 close earlier in the day. Management has yet to disclose the specific volume of shares to be offered or the target pricing for the round. Underwriters have been granted a 30-day window to purchase an additional 15% of the offering, a standard provision for such capital raises.

Capital generated from the sale is earmarked for the advancement of the company’s drug development pipeline. This move represents a strategic pivot for the biotechnology firm as it seeks to translate its recent market momentum into sustained funding for its clinical research programs.